The study has fully enrolled into the third dose cohort, each cohort includes3 patients. Treatment comprises 3 primary injections (days, 1, 15 and 29), aday 64 vaccination and from there a maintenance treatment every 2 months(see Figure 4). No dose limiting toxicity, or any significant vaccination relatedadverse event have been reported. Minor, grade 1 injection site reactionwere reported with a duration of 1 day.
Overall, the treatment is well tolerated, and the study will therefore moveinto the expansion cohort enrolling 10 patients into the optimal biologicaldose, to confirm safety response and the development of PD1-antibody incorrelation to response.
Ann: PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting, page-4
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $516.0M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.3¢ | 7.0¢ | $445.8K | 6.267M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1804981 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.2¢ | 424452 | 3 |
View Market Depth
| Last trade - 11.32am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.002 ( 1.41 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.3¢ | 7.0¢ | 2789521 | ||
| Last updated 11.50am 16/05/2024 ? | |||||
| IMU (ASX) Chart |